vs
INTEGRA LIFESCIENCES HOLDINGS CORP（IART）与EPLUS INC（PLUS）财务数据对比。点击上方公司名可切换其他公司
EPLUS INC的季度营收约是INTEGRA LIFESCIENCES HOLDINGS CORP的1.4倍（$614.8M vs $434.9M），EPLUS INC同比增速更快（20.3% vs -1.7%），过去两年INTEGRA LIFESCIENCES HOLDINGS CORP的营收复合增速更高（8.6% vs 2.3%）
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
ePlus Inc.是美国的科技咨询解决方案提供商，业务覆盖网络安全、云计算、网络架构、协作办公、人工智能及前沿技术领域，为超5000家客户提供定制化解决方案、专业咨询与托管服务，助力企业实现数字化转型与技术升级。
IART vs PLUS — 直观对比
营收规模更大
PLUS
是对方的1.4倍
$434.9M
营收增速更快
PLUS
高出22.1%
-1.7%
两年增速更快
IART
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $434.9M | $614.8M |
| 净利润 | — | $35.1M |
| 毛利率 | 50.8% | 25.8% |
| 营业利润率 | 5.3% | 7.1% |
| 净利率 | — | 5.7% |
| 营收同比 | -1.7% | 20.3% |
| 净利润同比 | — | 45.2% |
| 每股收益（稀释后） | $-0.03 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IARTPLUS
| Q4 25 | $434.9M | $614.8M | ||
| Q3 25 | $402.1M | $608.8M | ||
| Q2 25 | $415.6M | $637.3M | ||
| Q1 25 | $382.7M | — | ||
| Q4 24 | $442.6M | $493.2M | ||
| Q3 24 | $380.8M | $493.4M | ||
| Q2 24 | $418.2M | $535.7M | ||
| Q1 24 | $368.9M | — |
净利润IARTPLUS
| Q4 25 | — | $35.1M | ||
| Q3 25 | $-5.4M | $34.9M | ||
| Q2 25 | $-484.1M | $37.7M | ||
| Q1 25 | $-25.3M | — | ||
| Q4 24 | — | $24.1M | ||
| Q3 24 | $-10.7M | $31.3M | ||
| Q2 24 | $-12.4M | $27.3M | ||
| Q1 24 | $-3.3M | — |
毛利率IARTPLUS
| Q4 25 | 50.8% | 25.8% | ||
| Q3 25 | 51.5% | 26.6% | ||
| Q2 25 | 50.4% | 23.3% | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 56.3% | 25.4% | ||
| Q3 24 | 52.6% | 25.8% | ||
| Q2 24 | 54.0% | 23.7% | ||
| Q1 24 | 56.1% | — |
营业利润率IARTPLUS
| Q4 25 | 5.3% | 7.1% | ||
| Q3 25 | 2.9% | 8.0% | ||
| Q2 25 | -123.4% | 5.7% | ||
| Q1 25 | -4.0% | — | ||
| Q4 24 | 8.0% | 3.3% | ||
| Q3 24 | -2.1% | 5.5% | ||
| Q2 24 | -0.7% | 5.9% | ||
| Q1 24 | 1.1% | — |
净利率IARTPLUS
| Q4 25 | — | 5.7% | ||
| Q3 25 | -1.3% | 5.7% | ||
| Q2 25 | -116.5% | 5.9% | ||
| Q1 25 | -6.6% | — | ||
| Q4 24 | — | 4.9% | ||
| Q3 24 | -2.8% | 6.3% | ||
| Q2 24 | -3.0% | 5.1% | ||
| Q1 24 | -0.9% | — |
每股收益（稀释后）IARTPLUS
| Q4 25 | $-0.03 | $1.33 | ||
| Q3 25 | $-0.07 | $1.32 | ||
| Q2 25 | $-6.31 | $1.43 | ||
| Q1 25 | $-0.33 | — | ||
| Q4 24 | $0.25 | $0.91 | ||
| Q3 24 | $-0.14 | $1.17 | ||
| Q2 24 | $-0.16 | $1.02 | ||
| Q1 24 | $-0.04 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $263.7M | $326.3M |
| 总债务越低越好 | $726.6M | — |
| 股东权益账面价值 | $1.0B | $1.1B |
| 总资产 | $3.6B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资IARTPLUS
| Q4 25 | $263.7M | $326.3M | ||
| Q3 25 | $267.9M | $402.2M | ||
| Q2 25 | $253.6M | $480.2M | ||
| Q1 25 | $273.3M | — | ||
| Q4 24 | $273.6M | $253.1M | ||
| Q3 24 | $277.6M | $187.5M | ||
| Q2 24 | $296.9M | $349.9M | ||
| Q1 24 | $663.1M | — |
总债务IARTPLUS
| Q4 25 | $726.6M | — | ||
| Q3 25 | $736.3M | — | ||
| Q2 25 | $745.9M | — | ||
| Q1 25 | $755.6M | — | ||
| Q4 24 | $760.5M | — | ||
| Q3 24 | $765.3M | — | ||
| Q2 24 | $770.2M | — | ||
| Q1 24 | $775.0M | — |
股东权益IARTPLUS
| Q4 25 | $1.0B | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $962.3M | ||
| Q3 24 | $1.5B | $947.0M | ||
| Q2 24 | $1.5B | $921.9M | ||
| Q1 24 | $1.6B | — |
总资产IARTPLUS
| Q4 25 | $3.6B | $1.8B | ||
| Q3 25 | $3.6B | $1.8B | ||
| Q2 25 | $3.7B | $1.8B | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.0B | $1.8B | ||
| Q3 24 | $4.1B | $1.7B | ||
| Q2 24 | $4.1B | $1.7B | ||
| Q1 24 | $4.1B | — |
负债/权益比IARTPLUS
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.8M | $-87.4M |
| 自由现金流经营现金流 - 资本支出 | $-5.4M | — |
| 自由现金流率自由现金流/营收 | -1.2% | — |
| 资本支出强度资本支出/营收 | 4.0% | — |
| 现金转化率经营现金流/净利润 | — | -2.49× |
| 过去12个月自由现金流最近4个季度 | $-31.1M | — |
8季度趋势，按日历期对齐
经营现金流IARTPLUS
| Q4 25 | $11.8M | $-87.4M | ||
| Q3 25 | $40.9M | $-34.8M | ||
| Q2 25 | $8.9M | $-99.0M | ||
| Q1 25 | $-11.3M | — | ||
| Q4 24 | $50.7M | $65.7M | ||
| Q3 24 | $22.5M | $-21.6M | ||
| Q2 24 | $40.4M | $97.1M | ||
| Q1 24 | $15.8M | — |
自由现金流IARTPLUS
| Q4 25 | $-5.4M | — | ||
| Q3 25 | $25.8M | — | ||
| Q2 25 | $-11.2M | — | ||
| Q1 25 | $-40.2M | — | ||
| Q4 24 | $21.1M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $291.0K | — |
自由现金流率IARTPLUS
| Q4 25 | -1.2% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -10.5% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 0.1% | — |
资本支出强度IARTPLUS
| Q4 25 | 4.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | 4.2% | — |
现金转化率IARTPLUS
| Q4 25 | — | -2.49× | ||
| Q3 25 | — | -1.00× | ||
| Q2 25 | — | -2.63× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.72× | ||
| Q3 24 | — | -0.69× | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
